ISTH/LinkedIn
Sep 8, 2026, 07:02
Emerging Therapies in Thrombosis – Factor XI/XIa Inhibitor Trials – ISTH
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn:
“From the coagulation cascade to the latest clinical trials, take a closer look at the evolving science of Factor XI and Factor XIa inhibition.
In this on-demand session, Dr. Weitz provides a concise overview of FXI/FXIa inhibitors and compares some of the leading investigational therapies currently under evaluation.
See the evidence come to life through animated charts highlighting recent clinical data, study findings and the potential implications for anticoagulant therapy.
What could this emerging therapeutic approach mean for clinical practice?”
Other posts featuring ISTH on Hemostasis Today.
-
Sep 8, 2026, 06:54Dmitrii V Kalinin: Cryo-EM Reveals Dynamic Conformational Ensemble of Full-Length FXIa
-
Sep 8, 2026, 06:51Michael O’Shea: Safety of DOACs Versus Warfarin in Adults with Congenital Heart Disease
-
Sep 8, 2026, 02:49Jared Rice: High Platelets, Low Clot Risk? – What Makes Neonatal Platelets Different in Sepsis
-
Sep 8, 2026, 02:46Rasha E.: Exploring Polycythemia Vera: Beyond the Hematocrit
-
Sep 8, 2026, 02:35Ahmet Davut Aksu: Plasminogen Supplementation Enhances Alteplase Efficacy in Systemic Embolization Model
-
Sep 7, 2026, 23:56Abdel Gaffar Mohammed: Treatment Approaches for Different Types of TMA
-
Sep 7, 2026, 18:36Richard Kollen: Preventing Deep Vein Thrombosis During Long Flights
-
Sep 7, 2026, 18:34Mahmoud Hashem: Apixaban – Doses According to the Reason for Use
-
Sep 7, 2026, 18:31Julian P. Villacastin: LAAC as a Treatment Option When Long-Term Anticoagulation Is Problematic